Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Open-market sale Chief Scientific Officer sold 5,336 shares at an average $41.27 ($220,201)
  2. 4 Open-market sale Chief Commercial Officer sold 5,400 shares at an average $41.22 ($222,607)
  3. 4 Open-market sale Chief Accounting Officer sold 5,370 shares at an average $41.26 ($221,579)
  4. 5 Insider Annual Insider Trading Report
  5. 4 Open-market sale Chief Commercial Officer sold 48,910 shares at $41.19 ($2,014,603)
  6. 4 Open-market sale Chief Medical Officer sold 54,849 shares at $41.19 ($2,259,230)
  7. 4 Grant or award Chief Executive Officer acquired 147,000 shares (grant or award)
  8. 4 Grant or award Atillasoy Ercem acquired 28,000 shares (grant or award)
  9. 4 Grant or award Chief Medical Officer acquired 43,750 shares (grant or award)
  10. 4 Grant or award Director acquired 58,800 shares (grant or award)
  11. 4 Grant or award Chief Accounting Officer acquired 17,500 shares (grant or award)
  12. 4 Grant or award Chief Scientific Officer acquired 28,000 shares (grant or award)
  13. 4 Grant or award General Counsel acquired 28,000 shares (grant or award)
  14. 4 Grant or award Chief Commercial Officer acquired 35,000 shares (grant or award)
  15. 3/A Insider 3/A
  16. 4 Conversion Director acquired 2,436,773 shares (conversion)
  17. 4 Conversion Director acquired 5,532,757 shares (conversion)
  18. 4 Conversion Director acquired 20,583 shares (conversion)
  19. 4 Conversion General Counsel acquired 32,759 shares (conversion)
  20. 4 Conversion Chief Scientific Officer acquired 2,436,773 shares (conversion)

Page 16 of 19 · 363 filings